Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (315) 315
rosuvastatin calcium (293) 293
male (236) 236
fluorobenzenes - pharmacokinetics (225) 225
index medicus (207) 207
pharmacology & pharmacy (193) 193
animals (170) 170
rosuvastatin (153) 153
sulfonamides - pharmacokinetics (143) 143
pyrimidines - pharmacokinetics (141) 141
female (135) 135
pharmacokinetics (119) 119
adult (112) 112
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (111) 111
fluorobenzenes - therapeutic use (102) 102
middle aged (99) 99
fluorobenzenes - pharmacology (92) 92
rats (92) 92
fluorobenzenes - administration & dosage (88) 88
sulfonamides - therapeutic use (83) 83
pyrimidines - therapeutic use (82) 82
statins (79) 79
atorvastatin (77) 77
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (72) 72
pyrimidines - administration & dosage (72) 72
sulfonamides - administration & dosage (71) 71
fluorobenzenes - blood (69) 69
drug interactions (67) 67
fluorobenzenes - adverse effects (61) 61
aged (59) 59
pravastatin (59) 59
sulfonamides - pharmacology (58) 58
sulfonamides - blood (57) 57
pyrimidines - blood (56) 56
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (54) 54
pyrimidines - pharmacology (54) 54
simvastatin (54) 54
area under curve (52) 52
dose-response relationship, drug (52) 52
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (51) 51
sulfonamides - adverse effects (51) 51
pyrimidines - adverse effects (50) 50
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (47) 47
mice (44) 44
hypercholesterolemia - drug therapy (41) 41
treatment outcome (41) 41
atorvastatin calcium (39) 39
rats, sprague-dawley (39) 39
administration, oral (37) 37
cholesterol, ldl - blood (37) 37
fluorobenzenes - metabolism (37) 37
young adult (37) 37
hydroxymethylglutaryl-coa reductase inhibitors - blood (36) 36
cross-over studies (35) 35
sulfonamides (35) 35
organic anion transporters - metabolism (33) 33
time factors (33) 33
pyrimidines (32) 32
toxicology (32) 32
density-lipoprotein cholesterol (31) 31
fluorobenzenes - chemistry (31) 31
tissue distribution (31) 31
piperidines - pharmacokinetics (30) 30
cholesterol (29) 29
liver - metabolism (29) 29
safety (29) 29
clinical trials as topic (28) 28
efficacy (28) 28
metabolism (28) 28
adolescent (27) 27
cardiac & cardiovascular systems (27) 27
chemistry, analytical (27) 27
hypercholesterolemia (27) 27
organic anion transporters - genetics (27) 27
reproducibility of results (27) 27
antilipemic agents (26) 26
biochemistry & molecular biology (26) 26
coronary-heart-disease (26) 26
double-blind method (26) 26
fluorobenzenes (26) 26
lipids (26) 26
solute carrier organic anion transporter family member 1b1 (26) 26
healthy-volunteers (25) 25
hepatocytes - metabolism (25) 25
medicine, general & internal (25) 25
adult male-volunteers (24) 24
drug therapy, combination (24) 24
kinetics (24) 24
medicine, research & experimental (24) 24
analysis (23) 23
risk factors (23) 23
atp binding cassette transporter, sub-family g, member 2 (22) 22
brain - metabolism (22) 22
chromatography, high pressure liquid (22) 22
dogs (22) 22
dosage and administration (22) 22
pyrimidines - metabolism (22) 22
sulfonamides - metabolism (22) 22
anticholesteremic agents - therapeutic use (21) 21
hepatic-uptake (21) 21
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (412) 412
Russian (4) 4
Chinese (2) 2
French (2) 2
Japanese (2) 2
Dutch (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Saliva versus plasma pharmacokinetics: Theory and application of a salivary excretion classification system
by Idkaidek, Nasir and Arafat, Tawfiq
Molecular Pharmaceutics, ISSN 1543-8384, 08/2012, Volume 9, Issue 8, pp. 2358 - 2363
The aims of this work were to study pharmacokinetics of randomly selected drugs in plasma and saliva samples in healthy human volunteers, and to introduce a... 
Salivary Excretion Classification System | effective permeability | pharmacokinetics | protein binding | bioequivalence | SimCYP | MEDICINE, RESEARCH & EXPERIMENTAL | RELATIVE BIOAVAILABILITY | PERMEABILITY | CLINICAL PHARMACOKINETICS | BIOLOGICAL FLUID | DRUGS | PHARMACOLOGY & PHARMACY | Quinolines - blood | Acetates - blood | Fluorobenzenes - pharmacokinetics | Hydrochlorothiazide - pharmacokinetics | Triazoles - blood | Piroxicam - blood | Azithromycin - blood | Humans | Losartan - blood | Saliva - secretion | Male | Naphthalenes - blood | Benzhydryl Compounds - blood | Fluorobenzenes - pharmacology | Quinolines - pharmacokinetics | Sulfonamides - blood | Azithromycin - pharmacokinetics | Tolterodine Tartrate | Female | Triazoles - pharmacokinetics | Naphthalenes - pharmacokinetics | Piroxicam - analogs & derivatives | Sitagliptin Phosphate | Hydrochlorothiazide - blood | Losartan - pharmacokinetics | Benzhydryl Compounds - pharmacokinetics | Metformin - blood | Cresols - blood | Phenylpropanolamine - blood | Metformin - pharmacokinetics | Rosuvastatin Calcium | Cloxacillin - pharmacokinetics | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Cinacalcet Hydrochloride | Cloxacillin - blood | Saliva - metabolism | Pyrazines - pharmacokinetics | Piroxicam - pharmacokinetics | Pyrimidines - pharmacokinetics | Cresols - pharmacokinetics | Anthraquinones - blood | Anthraquinones - pharmacokinetics | Phenylpropanolamine - pharmacokinetics | Pyrazines - blood | Acetates - pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Drug interaction profile for GSK2248761, a next generation non‐nucleoside reverse transcriptase inhibitor
by Piscitelli, Steve and Kim, Joseph and Gould, Elizabeth and Lou, Yu and White, Scott and de Serres, Mark and Johnson, Mark and Zhou, Xiao‐Jian and Pietropaolo, Keith and Mayers, Douglas
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
by Keskitalo, JE and Zolk, O and Fromm, MF and Kurkinen, KJ and Neuvonen, PJ and Niemi, M
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 08/2009, Volume 86, Issue 2, pp. 197 - 203
The ABCG2 c.421C>A single‐nucleotide polymorphism (SNP) was determined in 660 healthy Finnish volunteers, of whom 32 participated in a pharmacokinetic... 
BCRP GENE POLYMORPHISMS | ACID | HUMAN PLASMA | SLCO1B1 POLYMORPHISM | LACTONE FORMS | TRANSPORTER ABCG2 | PHARMACOLOGY & PHARMACY | INDUCED MYOPATHY | CANCER RESISTANCE PROTEIN | SINGLE NUCLEOTIDE POLYMORPHISMS | P-GLYCOPROTEIN | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Pyrroles - urine | Area Under Curve | Drug Resistance, Multiple | Pyrimidines - blood | Heptanoic Acids - pharmacokinetics | Humans | Male | Reference Values | Fluorobenzenes - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | ATP-Binding Cassette Transporters - genetics | Sulfonamides - urine | Pyrroles - administration & dosage | Fluorobenzenes - urine | Heptanoic Acids - administration & dosage | Adult | Female | Fluorobenzenes - blood | Neoplasm Proteins - genetics | European Continental Ancestry Group - genetics | Pyrimidines - administration & dosage | Rosuvastatin Calcium | Genotype | Linear Models | Pyrroles - blood | Sulfonamides - pharmacokinetics | Cross-Over Studies | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Heptanoic Acids - urine | Finland | Pyrimidines - pharmacokinetics | Polymorphism, Single Nucleotide | Pyrimidines - urine | Heptanoic Acids - blood | Sulfonamides - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design
by Polli, Joseph W and Hussey, Elizabeth and Bush, Mark and Generaux, Grant and Smith, Glenn and Collins, David and McMullen, Susan and Turner, Nancy and Nunez, Derek J
Xenobiotica, ISSN 0049-8254, 6/2013, Volume 43, Issue 6, pp. 498 - 508
1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and... 
P-glycoprotein | BCRP | transporters | Cytochrome P450 | OATP | dyslipidemia | diabetes | pharmacogenetics | Pharmacogenetics | Dyslipidemia | Transporters | Diabetes | POLYMORPHISM MARKEDLY AFFECTS | SLCO1B1 POLYMORPHISM | ATORVASTATIN | INHIBITION | PHARMACOKINETICS | FLUVASTATIN | PHARMACOLOGY & PHARMACY | TOXICOLOGY | SIMVASTATIN | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Male | Heptanoic Acids - adverse effects | Simvastatin - pharmacology | Fluorobenzenes - pharmacology | Young Adult | Drug Interactions | Piperidines - pharmacology | Oxadiazoles - pharmacology | Madin Darby Canine Kidney Cells | Pyrroles - adverse effects | Oxadiazoles - pharmacokinetics | Heptanoic Acids - pharmacology | Mesylates - blood | Troleandomycin - adverse effects | Rosuvastatin Calcium | Mesylates - adverse effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Simvastatin - analogs & derivatives | Sulfonamides - pharmacokinetics | Oxadiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cytochrome P-450 CYP3A - metabolism | Adolescent | Atorvastatin | Pyrimidines - pharmacokinetics | Oxadiazoles - blood | Demography | Heptanoic Acids - pharmacokinetics | Mesylates - pharmacokinetics | Simvastatin - blood | Piperidines - blood | Troleandomycin - pharmacokinetics | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Reference Standards | Adult | Female | Piperidines - pharmacokinetics | Troleandomycin - pharmacology | Fluorobenzenes - blood | Pyrroles - blood | Simvastatin - pharmacokinetics | Pyrroles - pharmacology | Animals | Cytochrome P-450 CYP3A Inhibitors | Mesylates - pharmacology | Piperidines - adverse effects | Dogs | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Heptanoic Acids - blood
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Pharmacokinetics of cobicistat boosted‐elvitegravir administered in combination with rosuvastatin
by Custodio, Joseph M and Wang, Hui and Hao, Jia and Lepist, Eve‐Irene and Ray, Adrian S and Andrews, Jessica and Ling, Kah Hiing J and Cheng, Andrew and Kearney, Brian P and Ramanathan, Srinivasan
The Journal of Clinical Pharmacology, ISSN 0091-2700, 06/2014, Volume 54, Issue 6, pp. 649 - 656
Statins are commonly used medications by HIV‐1 patients. Elvitegravir/cobicistat/emtricitabine/tenofovir DF is a single tablet regimen for the treatment of... 
pharmacokinetics | organic anion transporting polypeptide | breast cancer resistance protein | Stribild | statins | elvitegravir | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Anti-HIV Agents - pharmacology | Fluorobenzenes - pharmacokinetics | Organic Anion Transporters, Sodium-Independent - antagonists & inhibitors | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Male | Neoplasm Proteins - antagonists & inhibitors | Carbamates - pharmacokinetics | Fluorobenzenes - pharmacology | Drug Interactions | Organic Anion Transporters, Sodium-Independent - metabolism | Quinolones - pharmacokinetics | Madin Darby Canine Kidney Cells | Solute Carrier Organic Anion Transporter Family Member 1B3 | Carbamates - pharmacology | Organic Anion Transporters - antagonists & inhibitors | Rosuvastatin Calcium | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Pyrimidines - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Cobicistat | ATP-Binding Cassette Transporters - antagonists & inhibitors | Thiazoles - blood | Cricetulus | Quinolones - pharmacology | Neoplasm Proteins - metabolism | Organic Anion Transporters - metabolism | Thiazoles - pharmacokinetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Quinolones - blood | Sulfonamides - blood | ATP-Binding Cassette Transporters - metabolism | Adult | Female | Anti-HIV Agents - blood | Drug Therapy, Combination | Fluorobenzenes - blood | CHO Cells | Carbamates - blood | Animals | Anti-HIV Agents - pharmacokinetics | Dogs | Thiazoles - pharmacology | Drug Combinations | Rosuvastatin | Dosage and administration | Pharmacokinetics | Analysis | Confidence intervals | Rodents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
by Pasanen, M K and Fredrikson, H and Neuvonen, P J and Niemi, M
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 12/2007, Volume 82, Issue 6, pp. 726 - 733
Thirty‐two healthy volunteers with different SLCO1B1 genotypes ingested a 20 mg dose of atorvastatin and 10 mg dose of rosuvastatin with a washout period of 1... 
COA REDUCTASE INHIBITOR | ANION TRANSPORTING POLYPEPTIDE | PLASMA-CONCENTRATIONS | PHARMACOLOGY & PHARMACY | HEPATIC-UPTAKE | TRANSPLANT RECIPIENTS | HEALTHY-VOLUNTEERS | INDUCED MYOPATHY | OATP-C SLC21A6 | SINGLE NUCLEOTIDE POLYMORPHISMS | CLINICAL-RELEVANCE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Fluorobenzenes - pharmacokinetics | Prospective Studies | Pyrroles - pharmacokinetics | Area Under Curve | Pyrimidines - blood | Heptanoic Acids - pharmacokinetics | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Male | Reference Values | Fluorobenzenes - administration & dosage | Organic Anion Transporters - metabolism | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Organic Anion Transporters - genetics | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Fluorobenzenes - blood | European Continental Ancestry Group - genetics | Administration, Oral | Pyrimidines - administration & dosage | Liver - metabolism | Rosuvastatin Calcium | Genotype | Pyrroles - blood | Sulfonamides - pharmacokinetics | Polymorphism, Genetic | Atorvastatin Calcium | Pyrimidines - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Heptanoic Acids - blood | Sulfonamides - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Functional Characterization of Mouse Organic Anion Transporting Peptide 1a4 in the Uptake and Efflux of Drugs Across the Blood-Brain Barrier
by Atsushi Ose and Hiroyuki Kusuhara and Chihiro Endo and Kimio Tohyama and Mari Miyajima and Satoshi Kitamura and Yuichi Sugiyama
Drug Metabolism and Disposition, ISSN 0090-9556, 01/2010, Volume 38, Issue 1, pp. 168 - 176
This study investigated the role of a multispecific organic anion transporter, Oatp1a4/ Slco1a4 , in drug transport across the blood-brain barrier. In vitro... 
LOCALIZATION | INVOLVEMENT | POLYPEPTIDE-2 | PENETRATION | PHARMACOLOGY & PHARMACY | RAT-BRAIN | OATP2 | BCRP/ABCG2 | 17-BETA-ESTRADIOL-D-17-BETA-GLUCURONIDE | CANCER RESISTANCE PROTEIN | P-GLYCOPROTEIN | Fluorobenzenes - pharmacokinetics | Gene Expression - genetics | Pyrimidines - blood | Humans | Ion Pumps - genetics | Fluorobenzenes - administration & dosage | Quinolines - administration & dosage | Pyrimidines - metabolism | Brain - metabolism | Quinolines - pharmacokinetics | Choroid Plexus - blood supply | ATP-Binding Cassette Transporters - genetics | Ochratoxins - administration & dosage | Cell Membrane - metabolism | Cerebral Cortex - drug effects | Capillaries - metabolism | Fluorobenzenes - metabolism | Tetrahydroisoquinolines - pharmacology | Organic Cation Transport Proteins - metabolism | Pravastatin - metabolism | Liver - metabolism | Rosuvastatin Calcium | Sulfonamides - pharmacokinetics | Blood-Brain Barrier - metabolism | Mice, Knockout | Brain - drug effects | Taurocholic Acid - administration & dosage | Pravastatin - administration & dosage | Enkephalin, D-Penicillamine (2,5)- - administration & dosage | Pyrimidines - pharmacokinetics | Mice | Kinetics | Organic Cation Transport Proteins - genetics | Pravastatin - pharmacokinetics | Sulfonamides - administration & dosage | Quinolines - blood | Digoxin - metabolism | Taurocholic Acid - metabolism | Choroid Plexus - metabolism | Taurocholic Acid - blood | Ochratoxins - pharmacokinetics | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Ochratoxins - metabolism | Cerebral Cortex - metabolism | Organic Anion Transporters - metabolism | Brain - blood supply | Sulfonamides - blood | Organic Anion Transporters - genetics | Transfection | Fluorobenzenes - blood | Enkephalin, D-Penicillamine (2,5)- - pharmacokinetics | Recombinant Proteins - metabolism | Cell Line | Pyrimidines - administration & dosage | Mice, Inbred C57BL | Recombinant Proteins - genetics | Blood-Brain Barrier - drug effects | Digoxin - pharmacokinetics | Quinolines - metabolism | Taurocholic Acid - pharmacokinetics | Liver - blood supply | Pharmaceutical Preparations - metabolism | Animals | Digoxin - administration & dosage | Enkephalin, D-Penicillamine (2,5)- - metabolism | Acridines - pharmacology | Sulfonamides - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy
by Romaine, S.P.R and Bailey, K.M and Hall, A.S and Balmforth, A.J
Pharmacogenomics Journal, ISSN 1470-269X, 02/2010, Volume 10, Issue 1, pp. 1 - 11
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are well established in the treatment of hypercholesterolaemia and the prevention of... 
SLCO1B1 | Statin | Transporter | Cholesterol | Myopathy | Polymorphism | REDUCTASE INHIBITORS | INTERINDIVIDUAL DIFFERENCES | myopathy | DRUG-INTERACTIONS | MULTIPLE-DOSE PRAVASTATIN | polymorphism | C SLC21A6 | LIPID-LOWERING EFFICACY | ANION TRANSPORTING POLYPEPTIDE | ABCB1 HAPLOTYPES | statin | transporter | GENETICS & HEREDITY | FUNCTIONAL-ANALYSIS | cholesterol | PHARMACOLOGY & PHARMACY | SINGLE NUCLEOTIDE POLYMORPHISMS | Haplotypes | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Heptanoic Acids - pharmacokinetics | Humans | Liver | Hepatocytes - metabolism | Hypercholesterolemia - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Pharmacogenetics | Gene Frequency | Rosuvastatin Calcium | Simvastatin - pharmacokinetics | Anticholesteremic Agents - adverse effects | Sulfonamides - pharmacokinetics | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Asian Continental Ancestry Group | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Pyrimidines - pharmacokinetics | Polymorphism, Single Nucleotide | HeLa Cells | Solute Carrier Organic Anion Transporter Family Member 1b1 | Pravastatin - pharmacokinetics | Research | Health aspects | Coronary heart disease | Genetic polymorphisms | Statins | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA
by Williamson, B and Soars, A. C and Owen, A and White, P and Riley, R. J and Soars, M. G
Xenobiotica, ISSN 0049-8254, 10/2013, Volume 43, Issue 10, pp. 920 - 931
Abstract 1. Organic anion transporting polypeptide 1B1 plays a pivotal role in the disposition of many anionic drugs. Significant overlap in substrate... 
drug transporters | organic anion polypeptides | drug-drug interactions | Cytochrome P450 | pharmacokinetics | siRNA | hepatocytes | OATP1B1 | Hepatocytes | Organic anion polypeptides | Drug-drug interactions | Pharmacokinetics | SiRNA | Drug transporters | PHARMACOKINETIC INTERACTION | ANGIOTENSIN-II AT1-RECEPTOR | TRANSPLANT RECIPIENTS | HEPATIC-UPTAKE | SANDWICH-CULTURED RAT | MOUSE VASCULAR ENDOTHELIUM | SMALL INTERFERING RNA | ANION-TRANSPORTING POLYPEPTIDE | IN-VITRO MODEL | PHARMACOLOGY & PHARMACY | TOXICOLOGY | Fluorobenzenes - pharmacokinetics | Valsartan | Humans | Molecular Sequence Data | Male | Hepatocytes - metabolism | Imidazoles - pharmacokinetics | Xenobiotics - pharmacokinetics | Organic Anion Transporters - metabolism | Quinolines - pharmacokinetics | Organic Anion Transporters - genetics | Drug Interactions | Base Sequence | Female | Hepatocytes - drug effects | Valine - pharmacokinetics | Valine - analogs & derivatives | Cells, Cultured | Rosuvastatin Calcium | Sulfonamides - pharmacokinetics | Estrone - analogs & derivatives | Cytochrome P-450 CYP3A - metabolism | Pyrimidines - pharmacokinetics | Liver-Specific Organic Anion Transporter 1 | Estrone - pharmacokinetics | RNA, Small Interfering - administration & dosage | Tetrazoles - pharmacokinetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
by Schneck, Dennis W and Birmingham, Bruce K and Zalikowski, Julie A and Mitchell, Patrick D and Wang, Yi and Martin, Paul D and Lasseter, Kenneth C and Brown, Colin D. A and Windass, Amy S and Raza, Ali
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 05/2004, Volume 75, Issue 5, pp. 455 - 463
Background Coadministration of statins and gemfibrozil is associated with an increased risk for myopathy, which may be due in part to a pharmacokinetic... 
REDUCTASE INHIBITORS | MALE-VOLUNTEERS | ORGANIC ANION TRANSPORTER | METABOLISM | PLASMA-CONCENTRATIONS | HUMAN HEPATOCYTES | COMBINATION THERAPY | PHARMACOLOGY & PHARMACY | CERIVASTATIN | PRAVASTATIN | RHABDOMYOLYSIS | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Xenopus | Fluorobenzenes - pharmacokinetics | Area Under Curve | Humans | Male | Reference Values | Fluorobenzenes - administration & dosage | Organic Anion Transporters - metabolism | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Cell Line - drug effects | Drug Interactions | Oocytes - drug effects | Adult | Female | Gemfibrozil - administration & dosage | Cell Line - metabolism | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Oocytes - metabolism | Pyrimidines - administration & dosage | Rosuvastatin Calcium | Gemfibrozil - pharmacology | Hypolipidemic Agents - pharmacology | Sulfonamides - pharmacokinetics | Cross-Over Studies | Animals | Hypolipidemic Agents - administration & dosage | Pyrimidines - pharmacokinetics | Sulfonamides - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
by Lee, Edmund and Ryan, Stephen and Birmingham, Bruce and Zalikowski, Julie and March, Ruth and Ambrose, Helen and Moore, Rachael and Lee, Caroline and Chen, Yusong and Schneck, Dennis
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 10/2005, Volume 78, Issue 4, pp. 330 - 341
Background Systemic exposure to rosuvastatin had been observed to be approximately 2‐fold higher in Japanese subjects living in Japan compared with white... 
ORGANIC ANION TRANSPORTER | COA REDUCTASE INHIBITOR | POPULATION | B SLC21A9 | ADULT MALE-VOLUNTEERS | PHARMACOLOGY & PHARMACY | PRAVASTATIN | OATP-C SLC21A6 | SINGLE NUCLEOTIDE POLYMORPHISMS | Fluorobenzenes - pharmacokinetics | Prospective Studies | Singapore | Area Under Curve | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Asian Continental Ancestry Group - genetics | Half-Life | Male | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Organic Anion Transporters - genetics | Adult | Female | Fluorobenzenes - blood | European Continental Ancestry Group - genetics | Gene Frequency | Rosuvastatin Calcium | Genotype | Sulfonamides - pharmacokinetics | Diet | Pyrimidines - pharmacokinetics | Environment | Polymorphism, Single Nucleotide | Solute Carrier Organic Anion Transporter Family Member 1b1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text More Potent Lipid-Lowering Effect by Rosuvastatin Compared With Fluvastatin in Everolimus-Treated Renal Transplant Recipients
by Robertsen, Ida and Åsberg, Anders and Granseth, Tone and Vethe, Nils Tore and Akhlaghi, Fatemeh and Ghareeb, Mwlod and Molden, Espen and Reier-Nilsen, Morten and Holdaas, Hallvard and Midtvedt, Karsten
Transplantation, ISSN 0041-1337, 06/2014, Volume 97, Issue 12, pp. 1266 - 1271
BACKGROUNDDyslipidemia is a risk factor for premature cardiovascular morbidity and mortality in renal transplant recipients (RTRs). Pharmacotherapy with mTOR... 
Renal transplantation | Lipid lowering | Rosuvastatin | Drug-drug interaction | Everolimus | Pharmacokinetic | SURGERY | MANAGEMENT | IMMUNOLOGY | ATORVASTATIN | TRANSPLANTATION | GLOMERULAR-FILTRATION-RATE | IN-VITRO | PHARMACOKINETICS | DISEASE | HEALTHY-VOLUNTEERS | DYSLIPIDEMIA | INHIBITORS | CYCLOSPORINE | Fluorobenzenes - pharmacokinetics | Prospective Studies | Humans | Immunosuppressive Agents - pharmacokinetics | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Dyslipidemias - blood | Drug Interactions | Fatty Acids, Monounsaturated - therapeutic use | Cytochrome P-450 CYP3A - genetics | Fatty Acids, Monounsaturated - adverse effects | Lipids - blood | Female | Dyslipidemias - etiology | Sirolimus - adverse effects | Dyslipidemias - drug therapy | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Rosuvastatin Calcium | Genotype | Treatment Outcome | Sirolimus - pharmacokinetics | Biomarkers - blood | Sulfonamides - pharmacokinetics | Phenotype | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Indoles - adverse effects | Sulfonamides - therapeutic use | Cytochrome P-450 CYP3A - metabolism | Norway | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Sulfonamides - adverse effects | Fatty Acids, Monounsaturated - pharmacokinetics | Immunosuppressive Agents - adverse effects | Indoles - pharmacokinetics | Indoles - therapeutic use | Aged | Fluorobenzenes - adverse effects | Drug Substitution | Fluorobenzenes - therapeutic use | Kidney Transplantation - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Pharmacokinetics, pharmacodynamics, safety, and tolerability of hyzetimibe (HS‐25) in healthy Chinese subjects
by Ruan, Zhourong and jiang, Bo and Chen, Jinliang and Zhang, Xuehua and Lou, Honggang and Xiang, Meixiang and Shao, Qingxiang and Wang, Jian'an
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2014, Volume 54, Issue 10, pp. 1144 - 1152
Hyzetimibe (HS‐25) is a new cholesterol absorption inhibitor. We performed the first‐in‐human study to assess the safety, tolerability, and pharmacokinetics... 
pharmacokinetics | cholesterol absorption inhibitor | first‐in‐human study | pharmacodynamics | hyzetimibe (HS‐25) | First-in-human study | Pharmacodynamics | Cholesterol absorption inhibitor | Pharmacokinetics | Hyzetimibe (HS-25) | hyzetimibe (HS-25) | first-in-human study | EVENTS | CHOLESTEROL LEVELS | PERSPECTIVES | DISEASE | PREVENTION | PHARMACOLOGY & PHARMACY | EZETIMIBE | Fluorobenzenes - pharmacokinetics | Double-Blind Method | Area Under Curve | Food-Drug Interactions | Humans | Azetines - pharmacology | Half-Life | Male | Fluorobenzenes - administration & dosage | Cross-Over Studies | Dose-Response Relationship, Drug | Fluorobenzenes - pharmacology | Young Adult | Anticholesteremic Agents - pharmacokinetics | Asian Continental Ancestry Group | Azetines - administration & dosage | Anticholesteremic Agents - administration & dosage | Azetines - pharmacokinetics | Adult | Cholesterol, LDL - blood | Female | Anticholesteremic Agents - pharmacology | Dose-response relationship (Biochemistry) | Pharmacology | Dosage and administration | Analysis | Anticholesteremic agents | Low density lipoprotein | Rodents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers
by P. A. Pham and C. J. L. la Porte and L. S. Lee and R. van Heeswijk and J. P. Sabo and M. M. Elgadi and P. J. Piliero and P. Barditch-Crovo and E. Fuchs and C. Flexner and D. W. Cameron
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 10/2009, Volume 53, Issue 10, pp. 4385 - 4392
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
LOCALIZATION | TRANSPORTER | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | HIV-1-INFECTED PATIENTS | TRANSPLANT RECIPIENTS | INHIBITORS | COMBINATION | RHABDOMYOLYSIS | CANCER RESISTANCE PROTEIN | ABCG2 | CYCLOSPORINE | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Pyridines - pharmacokinetics | Male | Heptanoic Acids - adverse effects | Young Adult | Pyridines - adverse effects | Drug Interactions | Ritonavir - adverse effects | Pyrroles - adverse effects | Adult | Female | Anti-HIV Agents - adverse effects | Rosuvastatin Calcium | Sulfonamides - pharmacokinetics | Atorvastatin Calcium | Pyrones - adverse effects |